| As the developed markets are becoming increasingly | | | | albeit at a lesser extent than developed countries. |
| mature, Pharma is turning to the emerging markets, | | | | Indonesia's economic prowess has resulted in the |
| where long-term growth can be sustained. Of | | | | country potentially joining the top tier of emerging |
| particular interest are Indonesia and the Philippines, | | | | markets including Brazil, Russia, India and China in the |
| which are currently going through major reforms to | | | | near future, as these are to grow at a faster rate than |
| expand their healthcare systems; however there are | | | | developed countries. |
| key differences between these two markets. | | | | With the introduction of a single South East Asian |
| Scope | | | | market via the free trade agreement Association of |
| *Provides a comparative overview of recent events | | | | South East Asian Nations (ASEAN) from 2011, in |
| affecting the macroeconomic and pharmaceutical | | | | addition to a full universal insurance coverage in the |
| landscape | | | | Philippines and Indonesia by 2010 and 2013, |
| *Examines different drivers and resistors for growth in | | | | respectively, the opportunity of pharmaceutical players |
| Indonesia and the Philippines | | | | to maximize sales will increase. |
| *Analyzes the growth drivers of multinational and | | | | Domestic pharmaceutical companies in both Indonesia |
| domestic players operating in these markets | | | | and the Philippines are ideal M&A targets for |
| *Identifies key strategies for entry and expansion in | | | | multinationals looking to enter or expand in these |
| these markets | | | | markets. This is due to their double digit sales growth, |
| Highlights | | | | which will be further fuelled by the growing demand for |
| The global economic downturn has impacted Indonesia, | | | | low cost medicine as healthcare coverage expands. |